Glecirasib and Ivonescimab for first-line KRAS G12C lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of two drugs (Glecirasib and Ivonescimab) as the first treatment for people with non-small cell lung cancer that has a specific mutation called KRAS G12C and has spread or can't be removed by surgery. The goal is to see if this combination helps shrink tumors or slow the cancer down.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been newly diagnosed with non-small cell lung cancer that has spread or cannot be removed by surgery.
- Your cancer has a specific mutation called KRAS G12C (a genetic change in the tumor).
- Your tumor has at least 1% PD-L1 (a protein that helps cancer hide from the immune system).
- You have not received any previous treatment for your advanced lung cancer.
- You are at least 18 years old and able to take care of yourself (ECOG score 0-2).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two targeted drugs (Fulzerasib and Ivonescimab) as a first treatment for advanced or metastatic lung cancer that has a specific KRAS G12C mutation. The goal is to see if this treatment works well and is safe.
This trial tests a new combination of two drugs (SKB264 and glecirasib) for people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12C. It aims to see if this combination can shrink tumors or slow their growth.
This trial tests a new approach for people with a specific type of lung cancer (KRAS G12C) that is still confined to the chest and can be surgically removed. It combines a targeted pill (garsorasib) followed by immunotherapy + chemotherapy before surgery, to see if this can shrink the tumor and improve outcomes.
This trial tests a new targeted pill (olomorasib) combined with immunotherapy (pembrolizumab) and possibly chemotherapy for people with advanced non-small cell lung cancer that has a KRAS G12C mutation and has not been treated before.
This trial tests if adding the targeted drug adagrasib to standard immunotherapy and chemotherapy helps people with a specific KRAS G12C mutation in non-squamous non-small cell lung cancer that has spread. It is for people who have not had previous treatment for advanced disease.
This trial tests a new drug called Ivonescimab as the first treatment for people with advanced (stage IV) non-small cell lung cancer whose tumors have high levels of PD-L1 (a protein that helps cancer hide from the immune system). The goal is to see if it can help shrink or control the cancer.
Hear when a new NSCLC Stage IV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.